β-Adrenoceptor and GRK3 expression in human lymphocytes is related to blood pressure and urinary albumin excretion

Journal of Hypertension

Volumn 28, Issue 6, 2010, Pages 1281-1289

  Oliver, Eduardo ^a   Rovira, Eduardo ^b   Montó, Fermí ^a   Valldecabres, Carmen ^b   Julve, Raul ^b   Muedra, Vicente ^b   Ruiz, Nuria ^c   Barettino, Domingo ^c   D'Ocon, Pilar ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL DE LA RIBERA   (Spain)

^c INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

Author keywords

Angiotensin converting enzyme inhibitors; GRK3; Hypertension; Urinary albumin excretion; adrenoceptors

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 3; G PROTEIN COUPLED RECEPTOR KINASE 5; MESSENGER RNA;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; LYMPHOCYTE; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 77952545616     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283383564     Document Type: Article

References (39)

1. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci 2006; 100:323-337.
2. Penela P, Murga C, Ribas C, Tutor AS, Peregrin S, Mayor F Jr. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc Res 2006; 69:46-56.
3. Feldman RD. Beta-adrenergic receptor alterations in hypertension- physiological and molecular correlates. Can J Physiol Pharmacol 1987; 65:1666-1672.
4. Feldman RD. Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet. J Clin Invest 1990; 85:647-652.
5. Gros R, Benovic JL, Tan CM, Feldamn RD. G-Protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest 1997; 99:2087-2093.
6. Oliver E, Marti D, Monto F, Flacco N, Moreno L, Barettino D, et al. The impact of alpha1-adrenoceptors up-regulation accompanied by the impairment of beta-adrenergic vasodilatation in hypertension. J Pharmacol Exp Ther 2009; 328:982-990.
7. Brodde OE, Stuka N, Demuth V, Fesel R,Bergerhausen J, Daul A,Bock KD. Alpha-and beta-adrenoceptors in circulating blood cells of essential hypertensive patients: increased receptor density and responsiveness. Clin Exp Hypertens A 1985; 7:1135-1150.
8. Parfyonova EV, Korichneva IL, Suvorov YI, Krasnikova TL. Characteristics of lymphocyte beta-adrenoceptors in essential hypertension: effects of propranolol treatment and dynamic exercise. Health Psychol 1988; 7 (Suppl):33-52.
9. Bono M, Cases A, Calls J, Gaya J, Jimenez W, Carretero J, et al. Effect of antihypertensive treatment on the increased beta 2-adrenoceptor density in patients with essential hypertension. Am J Hypertens 1995; 8:487-493.
10. Brodde OE, Kretsch R, Ikezono K, Zerkowski HR, Reidemeister JC. Human b-adrenoceptor: relation of myocardial and lymphocyte b-adrenoceptor density. Science 1986; 231:1584-1585.
11. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18:139-185.
12. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39:794-798.
13. Marti D, Miquel R, Ziani K, Gisbert R, Ivorra MD, Anselmi E, et al. Correlation between mRNA levels and functional roleof alpha1-adrenoceptor subtypes in arteries: evidence of alpha1L as a functional isoform of the alpha1A-adrenoceptor. Am J Physiol Heart Circ Physiol 2005; 289:H1923-H1932.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-408.
15. Yu XY, Lin SG, Wang XM, Liu Y, Zhang B, Lin QX, et al. Evidence for coexistence of three beta-adrenoceptor subtypes in human peripheral lymphocytes. Clin Pharmacol Ther 2007; 81:654-658.
16. Dzimiri N, Basco C, Moorji A, Afrane B, Al Halees Z. Characterization of lymphocyte beta 2-adrenoceptor signalling in patients with left ventricular volume overload disease. Clin Exp Pharmacol Physiol 2002; 29:181-188.
17. Wang TJ, Evans JC, Meigs JB, Rifai N, Fox CS, D'Agostino RB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111:1370-1376.
18. Schmieder RE, Schrader J, Zidek W, Tebbe U, Paar WD, Bramlage P, et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007; 96:247-257.
19. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32:219-226.
20. Perticone F, Maio R, Tripepi G, Sciacqua A, Mallamaci F, Zoccali C. Microalbuminuria, endothelial dysfunction and inflammation in primary hypertension. J Nephrol 2007; 20 (Suppl 12):S56-S62.
21. Hermans MM, Henry R, Dekker JM, Kooman JP, Kostense PJ, Nijpels G, et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol 2007; 18:1942-1952.
22. Hermans MM, Henry RM, Dekker JM, Nijpels G, Heine RJ, Stehouwer CD. Albuminuria, but not estimated glomerular filtration rate, is associated with maladaptive arterial remodeling: the Hoorn Study. J Hypertens 2008; 26:791-797.
23. Duman D, Demirtunc R, Karadag B, Karatas M. Association of albuminuria with impaired aortic elasticity and left ventricular diastolic dysfunction in type 2 diabetes. Anadolu Kardiyol Derg 2008; 8:10-15.
24. Gisbert R, Ziani K, Miquel R, Noguera MA, Ivorra MD, Anselmi E, D'Ocon P. Pathological role of a constitutively active population of alpha(1D)- adrenoceptors in arteries of spontaneously hypertensive rats. Br J Pharmacol 2002; 135:206-216.
25. God́inez-Hernández D, Gallardo-Ort́iz IA, Ló pez-Sánchez P, Villalobos-Molina R. Captopril therapy decreases both expression and function of alpha-adrenoceptors in pre hypertensive rat aorta. Auton Autacoid Pharmacol 2006; 26:21-29.
26. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46:1309-1315.
27. Binder A, Garcia E, Kazeem G, Ben-Shlmo Y, Yarnell J, Brown P, et al. Haplotypes of the beta-2 adrenergic receptor associate with high diastolic blood pressure in the Caerphilly prospective study. J Hypertens 2006; 24:471-477.
28. Hata JA, Williams ML, Schroder JN, Lima B, Keys JR, Blaxall BC, et al. Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lowerGRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J Card Fail 2006; 12:360-368.
29. Iaccarino G, Barbato E, Cipolletta E, De AV, Margulies KB, Leosco D, et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J 2005; 26:1752-1758.
30. Oppermann M, Diverse-Pierluissi M, Drazner MH, Dyer SL, Freedman NJ, Peppel KC, Lefkowitz RJ. Monoclonal antibodies reveal receptor specificity among G-protein-coupled receptor kinases. Proc Natl Acad Sci USA 1996; 93:7649-7654.
31. Bunemann M, Hosey MM. G-protein coupled receptor kinases as modulators of G-protein signalling. J Physiol 1999; 517 (Pt 1): 5-23.
32. Vinge LE, von Lueder TG, Aasum E,QvigstadE, Gravning JA, How OJ,et al. Cardiac-restricted expression of the carboxyl-terminal fragment of GRK3 uncovers distinct functions of GRK3 in regulation of cardiac contractility and growth: GRK3 controls cardiac alpha1-adrenergic receptor responsiveness. J Biol Chem 2008; 283:10601-10610.
33. Gros R, Tan CM, Chorazyczewski J, Kelvin DJ, Benovic JL, Feldman RD. G-protein-coupled receptor kinase expression in hypertension. Clin Pharmacol Ther 1999; 65:545-551.
34. Gros R, Chorazyczewski J, Meek MD, Benovic JL, Ferguson SS, Feldman RD. G-Protein-coupled receptor kinase activity in hypertension: increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension 2000; 35:38-42.
35. Oyama N, Urasawa K, Kaneta S, Sakai H, Saito T, Takagi C, et al. Chronic beta-adrenergic receptor stimulation enhances the expression of G-Protein coupled receptor kinases, GRK2 and GRK5, inboththe heart and peripheral lymphocytes. Circ J2005; 69:987-990.
36. Arnett DK, Devereux RB, Kitzman D, Oberman A, Hopkins P, Atwood L, et al. Linkage of left ventricular contractility to chromosome 11 in humans: The HyperGEN Study. Hypertension 2001; 38:767-772. (Pubitemid 34258668)
37. Iaccarino G, Rockman HA, Shotwell KF, Tomhave ED, Koch WJ. Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. Am J Physiol 1998; 275:H1298-H1306.
38. Eckhart AD, Duncan SJ, Penn RB, Benovic JL, Lefkowitz RJ, Koch WJ. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res 2000; 86:43-50.
39. Vinge LE, Andressen KW, Attramadal T,Andersen GO, Ahmed MS,Peppel K, et al. Substrate specificities of G protein-coupled receptor kinase-2 and-3 at cardiac myocyte receptors provide basis for distinct roles in regulation of myocardial function. Mol Pharmacol 2007; 72:582-591.